Epoetin Alfa in Treating Anemia in Patients With Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00058331
Recruitment Status : Completed
First Posted : April 9, 2003
Last Update Posted : July 18, 2016
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Alliance for Clinical Trials in Oncology

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 2006
  Actual Study Completion Date : May 2006
Publications of Results:
Steensma DP, Molina R, Sloan JA, et al.: A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) study N02C2. [Abstract] J Clin Oncol 23 (Suppl 16): A-8031, 736s, 2005.